Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3984662 | 1.00 | KCNH2 (0.64) | KCNH2HRH3 | |
| SCHEMBL3320331 | 0.91 | KCNH2 (0.71) | KCNH2HRH3 | |
| SCHEMBL3992684 | 0.91 | KCNH2 (0.71) | KCNH2HRH3 | |
| SCHEMBL14303502 | 0.89 | KCNH2 (0.63) | KCNH2HRH3 | |
| SCHEMBL3324671 | 0.89 | KCNH2 (0.63) | KCNH2HRH3 | |
| SCHEMBL3322990 | 0.88 | KCNH2 (0.65) | KCNH2HRH3 | |
| SCHEMBL14303879 | 0.88 | KCNH2 (0.65) | KCNH2HRH3 | |
| SCHEMBL3914407 | 0.84 | KCNH2 (0.61) | KCNH2HRH3 | |
| SCHEMBL1682267 | 0.82 | ALDH1A1 (0.52) | KCNH2HRH3 | |
| SCHEMBL1682261 | 0.82 | CNR2 (0.55) | KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035372-A1 | MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-03-18 | — | — | EP | claimed |
| WO-2008005338-A1 | MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | WO | claimed |
| US-20150011759-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | CEPHALON, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-20100121055-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | CEPHALON, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| EP-2152669-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | Cephalon, Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008137087-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | CEPHALON, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011759-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | TPMT, SPR, QDPR | KCNH2 783/4885HRH3 1100/4885 |
| US-20100121055-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | TPMT, SPR, QDPR | KCNH2 783/4885HRH3 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.